A client sits across from me a few months into estradiol, and asks the question underneath every other question they've been almost-asking for weeks: is this working right, or is something wrong with me. They've read three forums, two of them contradicting each other, and a fourth source that scared them badly enough that they stopped reading altogether. What they're actually describing — plateauing breast growth, a mood that feels bigger rather than simply happier, a timeline that refuses to match the influencer they've been quietly comparing themselves to — is not a malfunction. It is, almost point for point, the expected and well-documented texture of gender-affirming hormone therapy (GAHT). The distress isn't coming from their body doing something wrong. It's coming from nobody having told them, in plain and clinically grounded language, what "right" actually looks like.

This is the gap I want to close here: what actually happens in the body on GAHT, and what the profession's own governing clinical document — the WPATH SOC8, published 2022 — actually recommends, as opposed to what gets assumed, feared, or half-remembered from a decade-old blog post.

Folx seeking masculinization on testosterone will see three changes that are permanent regardless of dose or duration once they've occurred: a deepened voice, growth of facial and body hair, and clitoral/bottom growth of roughly one to two centimeters. Everything else — muscle mass, fat redistribution away from hips and thighs, cessation of menses, libido — requires ongoing administration to maintain and will recede, to varying degrees, if testosterone stops. None of this happens on a fixed clock. Lower doses track toward a slower, often more androgynous presentation; higher, consistently administered doses move faster. Genetics does a tremendous amount of the driving here, the same way it does in adolescent puberty, which is why two people on identical regimens can diverge wildly in beard density or vocal pitch drop.

The mirror-image process on estrogen has exactly one truly permanent change: breast tissue, which begins as budding around three months in and continues developing over two to three years. Everything else — softer skin, redistributed fat, decreased muscle mass, reduced spontaneous erections, testicular volume dropping 25–50% with long-term use — is dose-dependent and, again, not linear. And no, despite what half the internet insists, estrogen does not touch the voice. Vocal cords thickened by an endogenous testosterone puberty do not un-thicken; voice feminization work happens through training or surgery, full stop, and I tell clients this early so they're not waiting on a change that isn't coming from the hormone itself.

The clinical point underneath both of these timelines is one WPATH states directly in its hormone therapy chapter: the goal is to target serum hormone levels consistent with the individual's gender identity and embodiment goals, and — this matters — optimal target ranges have not been established. There is no single correct number, no universal finish line. Individualized dosing is not a hedge; it is the standard of care, explicitly.

I want to name something plainly because I watch it do damage in session after session: testosterone does not manufacture rage, and estrogen does not manufacture instability. These are inherited, patriarchal folk theories dressed up as biology — the same cultural reflex that pathologizes premenstrual cisgender women as "hysterical" gets redeployed, with barely a costume change, against trans folx on HRT. What clients on testosterone frequently report is something closer to emotional access changing shape: an easier route to a fuller range of feeling, sometimes alongside a genuinely reduced capacity to cry, which can register as relief or as loss depending on what the person valued about their own tears. What clients on estrogen frequently report is emotional amplitude — feelings landing bigger, more expansive, more felt-in-the-body — particularly in year one, often experienced as finally getting to feel something in a body that's starting to feel like home rather than a costume.

WPATH's own language on this point is unusually direct for a clinical document. The Standards state that hormone therapy has been found to positively affect the mental health and quality of life of TGD youth and adults, with hormone initiation linked to reduced depression, anxiety, and suicidality across multiple studies. More pointedly: SOC8 recommends against withholding hormone therapy while depression or suicidality gets "treated first" through conventional psychiatry alone, naming that sequencing as iatrogenic — meaning the withholding itself becomes the harm. If a client's mental health deteriorates while they're already on GAHT, the Standard is to maintain the existing hormone regimen and investigate the cause of the deterioration, not to reflexively discontinue treatment, unless something contraindicates continuing. That's a meaningfully different clinical posture than "hormones are the variable to suspect first," and it's worth knowing if you're the therapist a client turns to mid-crisis.

For folx who've been in this field or in transition long enough to remember SOC7, a few specific shifts are worth naming because they show up in what patients get told by prescribers now:

Ethinyl estradiol and conjugated equine estrogens are explicitly recommended against wherever bioidentical estradiol is available, on the strength of consistent data linking both to meaningfully elevated venous thromboembolism risk. If a client mentions either of these by name, that's worth a conversation with their prescriber, not a shrug.

Transdermal estrogen is specifically suggested — not just tolerated — for anyone over 45 or with a prior VTE history. This isn't caution theater; it's a response to real incidence data out of the Amsterdam cohort showing the risk dropping meaningfully after that switch.

Progesterone gets named honestly as a gap, not a given. Despite widespread anecdotal enthusiasm — and I hear this from clients constantly — SOC8's committed review found no quality evidence that progesterone improves breast development, mood, or libido in trans feminine people, while flagging real signal of harm with extended exposure. That doesn't mean no one should ever use it. It means "everyone says it helps" isn't clinical evidence, and clients deserve to know the difference between folklore and data when they're the ones taking the medication.

Fertility counseling is now a mandated part of initiation, not an optional add-on — before puberty suppression and before hormone therapy both. If a client tells you their prescriber never raised it, that's a gap worth naming.

Monitoring has a real cadence: labs roughly every three months through year one or with any dose change, dropping to one or two visits a year once an adult maintenance dose is stable. Clients who are getting monitored less than that, or far more anxiously than that, sometimes need to hear the actual standard out loud to recalibrate their own fear.

Most of what walks into my office wearing the shape of "something's wrong with my transition" is actually undifferentiated grief, impatience, or comparison — comparing an individualized, genetically variable, dose-dependent biological process against somebody else's highlight reel, or against a mental image of instant congruence that no endocrine system on earth delivers on anyone's timeline. The clinical task is rarely to reassure without content. It's to hand the client the actual shape of the thing — permanent changes here, contingent-on-continuation changes there, a documented range of normal variation, and a professional body's own admission that there is no fixed target to hit — so the anxiety has something real to land on instead of spinning against a vacuum. Folx don't need false comfort. They need the truth, delivered without alarm, from someone who actually read the chapter instead of repeating what everyone else half-remembers.

For folx who don't have local access to a gender-affirming prescriber, or whose local options have thinned out under political pressure, these are solid national starting points:

• FOLX Health — membership-based telehealth, LGBTQIA+-dedicated clinicians, accepts insurance for visits, medications, and labs.
• Plume — membership telehealth built exclusively for trans and gender-nonconforming folx, with prescribing clinicians and ongoing support.
• Planned Parenthood — telehealth GAHT at many (not all) affiliates, informed-consent access, broad insurance acceptance.
• QueerMed — evidence-based gender-affirming care for adults nationally, and for youth where state law permits.

Telehealth access for gender-affirming care is shifting at the state level with some regularity, so treat this as a starting point for a conversation rather than a guarantee — confirm current availability in your state directly with the provider before counting on a particular option.

This article is for educational purposes only and does not constitute medical advice or treatment. Mx. Love C. Dialogos is a Licensed Marriage and Family Therapist (LMFT), not a physician, nurse practitioner, or other prescribing provider, and holds no prescribing authority of any kind. Nothing here is intended to diagnose, treat, or replace an individualized care plan from a qualified hormone prescriber. If you are considering or currently undergoing gender-affirming hormone therapy, please consult directly with your prescribing provider. Clinical content is drawn from the WPATH Standards of Care, Version 8 (Coleman et al., 2022) and FOLX Health's patient education library, and is presented here in summary and adapted form rather than reproduced verbatim; readers are encouraged to consult those primary sources directly for full clinical detail.

Further reading on this site:

• Gender-Affirming Surgery: A Field Guide — procedures, recovery, and what to expect
• Being Non-Monosexual: Why the Middle Makes Everyone Else Uncomfortable — biphobia, erasure, and queer identity
• The Vice Grip: Intersectionality and Compounding Suicide Risk — why LGBTQ+ risk compounds with other marginalized identities
• Neutrality Isn't Neutral — the politics of clinical "neutrality" in LGBTQ+ affirming practice

Well wishes. 🙏

Mx. Love C. Dialogos, LMFT · Buddhist Chaplain Licensed Marriage and Family Therapist | Buddhist Chaplain Pronouns: They/Them